PD-1/PD-L1 Pathway in Breast Cancer

Oncology Research and Treatment

Volumn 40, Issue 5, 2017, Pages 294-297

  Schütz, Florian ^a   Stefanovic, Stefan ^a   Mayer, Luisa ^a   Von Au, Alexandra ^a   Domschke, Christoph ^a   Sohn, Christof ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Breast cancer; Immune checkpoints; Immunotherapy; PD1 PD L1

Indexed keywords

ATEZOLIZUMAB; BIOLOGICAL MARKER; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; APOPTOSIS; BREAST CARCINOGENESIS; CANCER PROGNOSIS; CELL MOTILITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION; HUMAN; IMMUNOLOGICAL TOLERANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNITY; UPREGULATION; ANIMAL; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; BREAST NEOPLASMS; CELL SURVIVAL; FEMALE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 85016585233     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000464353     Document Type: Review

References (43)

1. Ceeraz S, Nowak EC, Noelle RJ: B7 family checkpoint regulators in immune regulation and disease. Tends Immunol 2013; 34: 556-563.
2. Topalian SL, Drake CG, Pardoll DM: Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27: 450-461.
3. Jung K, Choi I: Emerging co-signaling networks in T cell immune regulation. Immune Netw 2013; 13: 184-193.
4. Tripathi S, Guleria I: Role of PD1/PD-L1 pathway, and Th17 and Treg cells in maternal tolerance to the fetus. Biomed J 2015; 38: 25-31.
5. Pentcheva-Hoang T, Corse E, Allison JP: Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009; 229: 67-87.
6. Fife BT, Bluestone JA: Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166-182.
7. Vonderheide R, LoRusso P, Khalil M, et al.: Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T-cells. Clin Cancer Res 2010; 16: 3485-3494.
8. McArthur HL, Diab A, Page DB, et al.: A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res 2016; 22: 5729-5737.
9. Parry RV, Chemnitz JM, Frauwirth KA, et al.: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25: 9543-9553.
10. Ishida Y, Agata Y, Shibahara K, et al.: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
11. Keir ME, Butte MJ, Freeman GJ, et al.: PD-1 and its ligands intolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
12. Freeman GJ, Wherry EJ, Ahmed R, et al.: Reinvigorating exhausted HIV-specific T-cells via PD-1-PD-L1 ligand blockade. J Exp Med 2006; 203: 2223-2227.
13. Butte MJ, Keir ME, Phamduy TB, et al.: Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122.
14. Freeman GJ, Long AJ, Iwai Y, et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
15. Latchman Y, Wood CR, Chernova T, et al.: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
16. Rodig N, Ryan T, Allen JA, et al.: Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 2003; 33: 3117-3126.
17. Zinselmeyer BH, Heydari S, Sacristan C, et al.: PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 2013; 210: 757-774.
18. Honda T, Egen JG, Lammermann T, et al.: Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity 2014; 40: 235-247.
19. Vibhakar R, Juan G, Traganos F, et al.: Activationinduced expression of human programmed death-1 gene in T-lymphocytes. Exp Cell Res 1997; 232: 25-28.
20. Wang J, Yoshida T, Nakaki F, et al.: Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A 2005; 102: 11823-11828.
21. Okazaki T, Tanaka Y, Nishio R, et al.: Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9: 1477-1483.
22. Day CL, Kaufmann DE, Kiepiela P, et al.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354.
23. Nishimura H, Nose M, Hiai H, et al.: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
24. Chang TT, Jabs C, Sobel RA, et al.: Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J Exp Med 1999; 190: 733-740.
25. Zielinski C, Knapp S, Mascaux C, et al.: Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013; 24: 1170-1179.
26. Sabatier R, Finetti P, Mamessier E, et al.: Prognostic and predictive value of PD-L1 expression in breast cancer. Oncotarget 2015; 6: 5449-5464.
27. Hamanishi J, Mandai M, Iwasaki M, et al.: Programmed cell death 1 ligand 1 and tumor-in filtrating CD8T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007; 104: 3360-3365.
28. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al.: Tumor-infiltrating NY-ESO-1-specific CD8 T cells are negatively regulated by LAG-3and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010; 107: 7875-7880.
29. Muenst S, Soysal SD, Gao F, et al.: The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013; 139: 667.
30. Emens L, Braiteh F, Cassier P, et al.: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Clin Cancer Res 2015; 75(suppl 15):2860.
31. Mittendorf E, Philips A, Meric-Bernstam F, et al.: PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014; 2: 361-370.
32. Iwai Y, Ishida M, Tanaka Y, et al.: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99: 12293-12297.
33. Kodumudi KN, Siegel J, Weber AM, et al.: Immune checkpoint blockade to improve tumor infiltrating lymphocytes for adoptive cell therapy. PLoS One 2016; 11:e0153053.
34. Topalian SL, Hodi FS, Brahmer JR, et al.: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
35. Costa R, Carneiro BA, Agulnik M, et al.: Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget 2017; 8: 8910-8920.
36. Denkert C, Loibl S, Noske A, et al.: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
37. Cimino-Mathews A, Foote J, Emens L: Immune targeting in breast cancer. Cancer Network 2015; 29: 375-385.
38. Lehmann B, Bauer J, Chen X, et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
39. Nanda R, Chow LQ, Dees EC, et al.: Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016; 34: 2460-2467.
40. Gibson J: Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol 2015; 16:e264.
41. Iwai Y, Ishida M, Tanaka Y, et al.: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99: 12293-12297.
42. Ma W, Gilligan BM, Yuan J, et al.: Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016; 9: 47.
43. Rothschild SI, Thommen S, Moersig W, et al.: Cancer immunology - development of novel anti-cancer therapies. Swiss Med Wkly 2015; 145:w14066.